Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Environmental, Social, Governance & Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Bone Marrow Conditioning
    • Clinical Trials
    • Illuccix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
    • Investor Centre
    • Financial Reports & Presentations
    • Corporate Governance
    • ASX Announcements
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home Events

News & Views

Latest News

Category: Events

See all

Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM

Clinical, Events, News,

Telix today announces presentations featuring the Company’s theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 – 13 September...

Read more

Join Telix at EANM 2023 to explore personalised diagnostics in urological cancers

Events, News,

Read more

New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC

Clinical, Events, News,

today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:...

Read more

Telix Urology Innovation Showcase Webcast

Events, News,

Telix is pleased to provide a video recording of the Company’s briefing session for shareholders held on Wednesday, June 21, 2023, at The Yale Club in New York City....

Read more

Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI

Events, News,

Telix today announces presentations from the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-targeting) and renal (carbonic anhydrase IX, or CAIX-targeting) diagnostic and therapeutic programs at the Society of Nuclear...

Read more

Telix Urology Innovation Showcase – June 21, 2023, at The Yale Club, New York City

ASX, Events, News,

Telix today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from...

Read more

Telix Opens European Radiopharmaceutical Production Facility

Events, News,

Telix today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company’s radiopharmaceutical production...

Read more

Telix to Present at Jefferies Healthcare Conference

Events, News,

Telix today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023. The presentation will take place on Wednesday...

Read more

Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology

Events, News,

Telix today announces it will host an education session for investors on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am – 12.30pm EDT.  Institutional investors, analysts and company guests are cordially...

Read more

Telix at ANZSNM 2023

Events, News,

Join Telix in Adelaide, South Australia, for the 53rd Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine from the 26th to the 28th of May. We...

Read more

Posts navigation

1 2 … 6

Subscribe

* indicates required
Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings

Recent legislative changes to the Corporations Act 2001 (Cth), which came into effect on 1 April 2022, mean there are new options available to shareholders as to how you elect to receive your communications from Telix. Telix will no longer send shareholders physical meeting documents unless you request a copy to be mailed.

Telix encourages shareholders to provide your email address so we can communicate with you electronically when shareholder notices become available online for such items as meeting documents, dividend statements (if applicable) and annual reports. You can make a standing election to receive some or all of your shareholder communications in physical or electronic form.

To review or update your current communication preference simply logon to our share registry’s website here. You will need your portfolio log in details or your Shareholder Reference Number (SRN) or Holder Identification Number (HIN). Once logged in, select the ‘communications’ tab at the top of the page.

If at any time you require an additional copy of a communication, or you need more information about the options available to you, you may contact Link Market Services via email at LMSComms@linkmarketservices.com.au